REPLY
23.3.2023 09:01:30 CET | Business Wire | Press release
The digital asset market is growing exponentially. Thanks to blockchain technology and the new generation of operators using tokenization platforms, it is possible to turn everything that can be digitally archived into a digital asset, with recognised value and established ownership. This is what emerges from Reply's new ‘Digital Assets Trends’ research, based on the Reply SONAR platform. By analysing industry studies, scientific articles, patents, documents, and B2B content published in the last year, and integrating concrete experiences from Reply's clients, the study examines the main trends related to digital assets.
Tokenization is the first step to bringing real-world assets and financial instruments onto the blockchain, representing an opportunity especially for those of an illiquid nature (e.g., high-value art, public infrastructure, private equity). The main advantages of tokens include the construction of a peer-to-peer network without intermediaries that also serves as a decentralised network, end-to-end traceability with the possibility of proving ownership at any time, and automated record-keeping that simplifies every aspect of compliance.
"Digital assets still constitute less than 1% of the global financial system, but they have already grown exponentially and will continue this trend in the years to come," commented Filippo Rizzante, CTO of Reply. "Today, Reply is already supporting the demands of various financial institutions, as well as some major players in healthcare, energy, fashion, and public administration, in the adoption of digital assets enabled by a growing maturity of the regulatory framework and the intense work of central banks on their digital currencies."
The study essentially identifies 4 macro-categories of emerging digital assets, these are: payment tokens, non-fungible tokens (NFTs), utility tokens, and security tokens.
Payment tokens include cryptocurrencies and stablecoins. These currencies have not yet been issued by governments or other financial institutions, but are monitored and organised on a decentralised network. This network also serves as a secure ledger for each transaction, pending the first regulations that will come into force in 2024. The rapid and increased circulation of this type of asset has pushed central banks to explore their digital currencies, namely the Central Bank Digital Currencies, and the ECB has also started developing pilot projects for a digital Euro.
Non-fungible tokens are a digital representation of real assets or natively digital assets to be collected or used in virtual worlds. NFTs find application in various sectors, including asset management and the art market. Currently, they are not subject to any regulation and find the greatest potential within the metaverse.
Utility tokens allow the user to perform an action on a specific blockchain or decentralised application. They have been particularly popular for so-called initial coin offerings (ICOs), but today they are mainly used to redeem services and digital products in predefined ecosystems, such as those of cloud or online gaming.
Security tokens are a digital representation of a traditional financial instrument (stocks, bonds and derivatives). As digital assets, they offer additional benefits, including greater flexibility in the creation and distribution process for SMEs and startups. In addition to the existing security tokens that the European Investment Bank launched, the Reply SONAR platform has identified a growing interest in the tokenization of carbon credits, which concern a typically opaque and inefficient market like blockchain technology. This could revolutionise the monetary side of the life cycle of a tokenized carbon offset by tokenizing the credits.
The ‘Digital Assets Trends’ research can be downloaded here.
This study is part of the ‘Reply Trend SONAR’ series, which includes ‘Digital Experience Trends 2023’, ‘Metaverse: the potential beyond the hype’, and ‘Sustainability Trends’.
Reply
Reply [EXM, STAR: REY] specialises in the design and implementation of solutions based on new communication channels and digital media. As a network of highly specialised companies, Reply defines and develops business models enabled by the new models of AI, big data, cloud computing, digital media and the internet of things. Reply delivers consulting, system integration and digital services to organisations across the telecom and media; industry and services; banking and insurance; and public sectors. www.reply.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230323005053/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
